PF-04236921
Phase 2Small molecule
PfizerPF-04236921 is one of 10 small molecule programs targeting Lupus Erythematosus. It is currently in Phase 2.
1
Indications
4
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Lupus Erythematosus
#DrugCompanyPhaseTrials
1Cibinqo
PfizerApproved
Venclexta
AbbVieApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Plaquenil
Alnylam PharmaceuticalsPhase 2
Enpatoran
Merck & Co.Phase 3
Telitacicept
VVor Biopharma
Phase 2
Nicotinamide
MMetro International Biotech, LLC
Phase 2
Atacicept
EMD SeronoPhase 2
PF-04236921
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tics1 trial
Efficacy and Safety1 trial
Lupus Erythematosus1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PF-04236921. EMBL-EBI & Wellcome Sanger Institute.
- [4]